Table 1 Clinicopathological variables of patient samples and expression of transgelin in lung cancer stroma.
Variables | Patients | TAGLN low (%) | TAGLN high (%) | χ2 | p value |
|---|---|---|---|---|---|
Age (years) | |||||
≥60 | 51 | 18 (35.29%) | 33 (64.71%) | 3.140 | 0.0764 |
<60 | 43 | 23 (53.49%) | 20 (46.51%) | Â | Â |
Gender | |||||
Male | 53 | 25 (47.17%) | 28 (52.83%) | 0.6237 | 0.4297 |
Female | 41 | 16 (39.02%) | 25 (60.98%) | Â | Â |
Size of tumor | |||||
<5 cm | 70 | 37 (52.86%) | 33 (47.14%) | 9.518 | 0.0020 |
≥5 cm | 24 | 4 (16.67%) | 20 (83.33%) |  |  |
Lymph node status | |||||
Negative | 43 | 28 (65.12%) | 15 (34.88%) | 14.90 | 0.0001 |
Positive | 51 | 13 (25.49%) | 38 (74.51%) | Â | Â |
T-primary tumor | |||||
T1 + T2 | 70 | 38 (54.29%) | 32 (45.71%) | 12.69 | 0.0004 |
T3 + T4 | 24 | 3 (12.5%) | 21 (87.5%) |  |  |
TNM stages | |||||
I–II | 51 | 31 (60.78%) | 20 (39.22%) | 13.36 | 0.0003 |
III–IV | 43 | 10 (23.26%) | 33 (76.74%) |  |  |
Pathological grade | |||||
I | 11 | 8 (72.73%) | 3 (27.27%) | 4.293 | 0.0383 |
II–III | 83 | 33 (39.76%) | 50 (60.24%) |  |  |
